TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24871380

Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 60 mJ
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 100 mJ
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 160 mJ
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Er:YAG laser debridement at 250 mJ
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ultrasonic treatment
Number of subjects: 64
Study: 22342411

Group type: EXPERIMENTAL
Intervention: ThuLEP (70 W)
Number of subjects: 133

Group type: COMPARATOR
Intervention: HoLEP (90 W)
Number of subjects: 133
Study: 20819082

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 2052

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 2052
Study: 17362556

Group type: EXPERIMENTAL
Intervention: Low serum beta-carotene concentrations
Number of subjects: 400
Study: 16379601

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil + HAART
Number of subjects: 6

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 6
Study: 12184481

Group type: EXPERIMENTAL
Intervention: Displayed emotion
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: High specificity speech
Number of subjects: 132
Study: 10459959

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice daily until labour, 600 mg at beginning of labour, and 300 mg twice daily for 7 days post partum)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 7639221

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension 2 g BID
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 2696630

Group type: EXPERIMENTAL
Intervention: Mitoxantrone containing multi-drug chemotherapy
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Mitoxantrone, methotrexate and 5-fluorouracil
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, mitoxantrone, vincristine and prednisone
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: UFT, mitoxantrone, mitomycin C
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Other malignancies treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Adriamycin or epirubicin combined with other drugs (control)
Number of subjects: 182
Study: 46962

Group type: EXPERIMENTAL
Intervention: Kveim test material
Number of subjects: 81
Study: 30876453

Group type: EXPERIMENTAL
Intervention: Physician consultation
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Waiting time
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Total service quality score
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Outpatient services assessment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Positive perception of service quality
Number of subjects: 400
Study: 28683228

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 2255

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 2255
Study: 26311628

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13600

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13600
Study: 23560258

Group type: EXPERIMENTAL
Intervention: XPB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CHX prior to XPB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: XEN
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CHX prior to XEN
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 20702754

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for 8 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg once daily for 6 days
Number of subjects: 2
Study: 19327379

Group type: EXPERIMENTAL
Intervention: Enhanced life functioning message
Number of subjects: 94

Group type: COMPARATOR
Intervention: Enhanced physical health message
Number of subjects: 94
Study: 16700666

Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B (NBUVB) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B (NBUVB) plus 0.05% topical calcipotriol ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: NBUVB alone
Number of subjects: 40
Study: 14715387

Group type: COMPARATOR
Intervention: PCA morphine 1 mg/ml
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: PCA morphine 1 mg/ml plus naloxone 0.6 microg/ml
Number of subjects: 265
Study: 11882754

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 300

Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 300
Study: 9669007

Group type: EXPERIMENTAL
Intervention: 3 mg granisetron (Group G)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol (Group D)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3 mg granisetron plus 1.25 mg droperidol (Group GD)
Number of subjects: 150
Study: 7636054

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg + Albuterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg + Albuterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg + Albuterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2794193

Group type: EXPERIMENTAL
Intervention: CAI (Computer-Assisted Instruction)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 76
Study: 322905

Group type: EXPERIMENTAL
Intervention: Premarin (conjugated equine oestrogens)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 30482933

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Acipimox
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-502-3p overexpression
Number of subjects: 22
Study: 28238711

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2‐90)
Number of subjects: 13199

Group type: COMPARATOR
Intervention: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2‐90)
Number of subjects: 13199

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13199

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13199
Study: 26394188

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS)
Number of subjects: 4317

Group type: EXPERIMENTAL
Intervention: Refinement of previously reported region
Number of subjects: 4317
Study: 24088368

Group type: COMPARATOR
Intervention: Intensive Insulin Therapy (IIT) protocol presumed if median Glu₁ <6.44 mmol/L
Number of subjects: 176505

Group type: COMPARATOR
Intervention: Control arm of NICE‐SUGAR trial
Number of subjects: 176505

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 176505
Study: 22069132

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy with medication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medication (tricyclic antidepressants or selective serotonin reuptake inhibitors)
Number of subjects: 50
Study: 19726448

Group type: EXPERIMENTAL
Intervention: Letrozole combined with norethisterone acetate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Norethisterone acetate alone
Number of subjects: 82
Study: 17698578

Group type: EXPERIMENTAL
Intervention: audio computer-assisted self-interviewing
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: face-to-face interview with study staff
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: self-administered paper-and-pencil questionnaire
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: interview by study staff about adherence within the previous 24 hours
Number of subjects: 104
Study: 15328251

Group type: EXPERIMENTAL
Intervention: Valerian extract (1000 mg nightly for 14 days)
Number of subjects: 12
Study: 11432623

Group type: EXPERIMENTAL
Intervention: High-dose platinum (cisplatin and carboplatin)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 280
Study: 9492500

Group type: EXPERIMENTAL
Intervention: High concentration sevoflurane (2.0% for 60 sec before and after pause)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sevoflurane (1.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low flow sevoflurane (0.5 l.min‐1 during pause)
Number of subjects: 0
Study: 9138869

Group type: EXPERIMENTAL
Intervention: Goserelin injections (3 doses of 3.6 mg subcutaneously at 4-week intervals) followed by hysteroscopic resection if fibroids remained submucous.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with normal uterine cavity.
Number of subjects: 100
Study: 30019265

Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) programme, 4 months of weekly classes of 45 min
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) programme
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual lifestyle activity (Control)
Number of subjects: 186
Study: 27965257

Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab 150 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab 75 mg
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Secukinumab (combined groups)
Number of subjects: 371
Study: 25877278

Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention (PRCI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 50
Study: 23516997

Group type: EXPERIMENTAL
Intervention: Mastery-oriented climate
Number of subjects: 108

Group type: COMPARATOR
Intervention: Performance-oriented climate
Number of subjects: 108
Study: 21328040

Group type: EXPERIMENTAL
Intervention: Survivor Health and Resilience Education Program (SHARE) intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 75
Study: 19223739

Group type: EXPERIMENTAL
Intervention: Paclitaxel injection NK
Number of subjects: 0

Group type: COMPARATOR
Intervention: Taxol injection
Number of subjects: 0
Study: 16603828

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study: 12622764

Group type: EXPERIMENTAL
Intervention: Triple therapy (rabeprazole 20 mg b.d., rifabutin 300 mg once daily, levofloxacin 500 mg once daily for 7 days)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Quadruple therapy (rabeprazole 20 mg b.d., metronidazole 400 mg t.d.s., bismuth subcitrate 120 mg q.d.s., tetracycline 500 mg q.d.s. for 7 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 109
Study: 10833553

Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9339085

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises with urethral biofeedback for 8 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pelvic muscle exercises alone
Number of subjects: 39
Study: 8411891

Group type: EXPERIMENTAL
Intervention: ICCE with ACL
Number of subjects: 360

Group type: COMPARATOR
Intervention: ECCE with PCL
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 360
Study: 3513720

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 28716428

Group type: EXPERIMENTAL
Intervention: High-intensity statin treatment (40mg atorvastatin)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Low-intensity statin treatment (20mg pravastatin)
Number of subjects: 2000
Study: 26928074

Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with aluminum hydroxide
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (5/5/5 μg or 20/20/20 μg) with MF59(®)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study: 24907703

Group type: EXPERIMENTAL
Intervention: GOLE model presentations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group presentations
Number of subjects: 0
Study: 22264496

Group type: EXPERIMENTAL
Intervention: Interview for Deterioration in Daily Living Activities in Dementia (IDDD)
Number of subjects: 301
Study: 20359934

Group type: EXPERIMENTAL
Intervention: Dysport (500 units)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 18555114

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker verapamil (100 microg injected into renal artery)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no verapamil)
Number of subjects: 96
Study: 16133638

Group type: EXPERIMENTAL
Intervention: Milk Basic Protein (MBP) 40 mg per day for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milk Basic Protein (MBP)
Number of subjects: 32
Study: 12234091

Group type: EXPERIMENTAL
Intervention: modified constraint-induced therapy (mCIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: regular therapy (TR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: no therapy (CON)
Number of subjects: 14
Study: 10196785

Group type: EXPERIMENTAL
Intervention: 1-stage surgical procedure and immediate loading (Experimental Group - EG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 2-stage surgical procedure (Reference Group - RG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (EG and RG)
Number of subjects: 27
Study: 7495630

Group type: EXPERIMENTAL
Intervention: Direct composite inlays
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional composite restorations
Number of subjects: 142
Study: 2334030

Group type: EXPERIMENTAL
Intervention: Pregnanolone emulsion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 6
Study: 291771

Group type: EXPERIMENTAL
Intervention: D-ZAPO induction program (daunomycin, 5-azacytidine, cytosine arabinoside, prednisone, and vincristine)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Immunotherapy (BCG and allogenic acute myelomonocytic leukemic cells)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 163
Study: 31575574

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 2346

Group type: COMPARATOR
Intervention: Conventional in vitro fertilisation (IVF)
Number of subjects: 2346
Study: 29202867

Group type: EXPERIMENTAL
Intervention: 4Rs and 2Ss Multiple Family Group (MFG) intervention
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Clinic Implementation Team (CIT) adaptation
Number of subjects: 2688
Study: 26452709

Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 units subcutaneously once per week for a maximum of three doses)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride subcutaneously once per week for a maximum of three doses)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 24460808

Group type: EXPERIMENTAL
Intervention: Continuous ECG monitoring during standing response
Number of subjects: 40

Group type: COMPARATOR
Intervention: Brisk supine to standing response
Number of subjects: 40
Study: 22924372

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplements (1 gr daily for three months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19180855

Group type: EXPERIMENTAL
Intervention: Suspension seat
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fixed seat
Number of subjects: 12
Study: 17718695

Group type: EXPERIMENTAL
Intervention: Withdrawal of antiepileptic drugs (AEDs)
Number of subjects: 39
Study: 15249567

Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg once daily (plus stavudine placebo twice daily) (n = 286)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Stavudine at standard doses twice daily (plus emtricitabine placebo once daily) (n = 285)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Emtricitabine group
Number of subjects: 571

Group type: COMPARATOR
Intervention: Stavudine group
Number of subjects: 571
Study: 11573924

Group type: EXPERIMENTAL
Intervention: DonJoy Legend brace
Number of subjects: 31

Group type: COMPARATOR
Intervention: Mechanical placebo brace
Number of subjects: 31

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All groups (DonJoy Legend brace, Mechanical placebo brace, No brace)
Number of subjects: 31
Study: 9363379

Group type: EXPERIMENTAL
Intervention: Low fat exercise (LFEX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low fat control (LFC)
Number of subjects: 21
Study: 8317714

Group type: EXPERIMENTAL
Intervention: Positive needle polarity
Number of subjects: 10

Group type: COMPARATOR
Intervention: Negative needle polarity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of mean ratio of positive to negative threshold stimulation current
Number of subjects: 10
Study: 3551551

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg for 7 nights
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chlormethiazole 384 mg for 7 nights
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for 7 nights
Number of subjects: 62
Study: 30924492

Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29079379

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 27616196

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 37.5 mg
Number of subjects: 2148

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg
Number of subjects: 2148

Group type: COMPARATOR
Intervention: Lebrikizumab (both doses)
Number of subjects: 2148
Study: 24135768

Group type: EXPERIMENTAL
Intervention: 6 months of daily isoniazid preventive therapy (IPT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both IPT and Observation
Number of subjects: 82
Study: 21414109

Group type: EXPERIMENTAL
Intervention: Electronic prescribing system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no electronic prescribing system)
Number of subjects: 26
Study: 20697947

Group type: EXPERIMENTAL
Intervention: Retention enema with Huchang Jiedu Decoction (HJD), once every day for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional integrative medicine
Number of subjects: 60
Study: 17654087

Group type: EXPERIMENTAL
Intervention: 28 selected male and female trisyllabic Taiwan Mandarin words
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Familiar trisyllabic words recorded at 14 intensity levels (‐10 to 16 dB HL)
Number of subjects: 20
Study: 15808031

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 12480010

Group type: EXPERIMENTAL
Intervention: Toomey™ syringe after gastric insufflation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Toomey™ syringe before gastric insufflation
Number of subjects: 0
Study: 10417749

Group type: EXPERIMENTAL
Intervention: Becaplermin gel 100 microg/g once daily
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Becaplermin gel 300 microg/g once daily
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Becaplermin gel 100 microg/g twice daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo gel (sodium carboxymethylcellulose)
Number of subjects: 124
Study: 7496281

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (6 to 16 sessions)
Number of subjects: 79
Study: 2107830

Group type: EXPERIMENTAL
Intervention: L‐carnitine supplemented formula (600 nmol/ml, for 7 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplementation)
Number of subjects: 29
Study: 540521

Group type: EXPERIMENTAL
Intervention: Xanthinol nicotinate (2400 mg daily for 10 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (8 tablets daily for 10 weeks)
Number of subjects: 16
Study: 29971469

Group type: EXPERIMENTAL
Intervention: Vitamin E vaginal suppository
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 52
Study: 28019010

Group type: COMPARATOR
Intervention: Selumetinib 50 mg (renal impairment study)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Selumetinib (20-50 mg depending on liver dysfunction) (hepatic impairment study)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Selumetinib (before dialysis)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Selumetinib (after dialysis)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Selumetinib (both studies)
Number of subjects: 56
Study: 26448616

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination/selective oropharyngeal decontamination
Number of subjects: 557

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Carbapenem exposure
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: P. aeruginosa
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Klebsiella species
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Enterobacter species
Number of subjects: 557
Study: 24040948

Group type: EXPERIMENTAL
Intervention: SHED (stem cells from human exfoliated deciduous teeth)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 21479690

Group type: EXPERIMENTAL
Intervention: Intraoperative epidural analgesia (EA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous analgesia (IA)
Number of subjects: 35
Study: 19817194

Group type: EXPERIMENTAL
Intervention: Massage therapy and horizontal bar exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 120